Inclusion Criteria

Inclusion criteria:

- locally advanced irresectable or metastatic renal cell cancer

- no untreated brain metastases (CT or MRI not necessary in the absence of symptoms)

- no uncontrolled hypertension

- no clinically significant cardiovascular events or disease during the last 12 months

- no surgery in the last 4 weeks

- no treatment with bevacizumab or another monoclonal antibody with anti-angiogenic
properties in the last 4 months

- no treatment with a tyrosine kinase inhibitor during the last 4 weeks

- measurable disease with x-ray or CT scan, at least one site of disease must be
unidimensionally measurable as follows: X-ray > 20 mm, Spiral CT scan > 10 mm,
non-spiral CT scan > 20 mm

- clear cell histology component

- not pregnant or nursing

- women of childbearing potential must use effective contraception

- absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial

- before patient randomization, written informed consent must be given according to
GCP, and local regulations